Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium

• Published in: American journal of hematology Vol. 97; no. 5; pp. 613 - 622
• Main Authors: Pommert, Lauren, Schafer, Eric S., Malvar, Jemily, Gossai, Nathan, Florendo, Ellynore, Pulakanti, Kirthi, Heimbruch, Katelyn, Stelloh, Cary, Chi, Yueh‐Yun, Sposto, Richard, Rao, Sridhar, Huynh, Van Thu, Brown, Patrick, Chang, Bill H., Colace, Susan I., Hermiston, Michelle L., Heym, Kenneth, Hutchinson, Raymond J., Kaplan, Joel A., Mody, Rajen, O'Brien, Tracey A., Place, Andrew E., Shaw, Peter H., Ziegler, David S., Wayne, Alan, Bhojwani, Deepa, Burke, Michael J.
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.05.2022; Wiley Subscription Services, Inc
• Subjects: 5-aza-2'-deoxycytidine; Acute myeloid leukemia; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Biological activity; Chemoresistance; Chemotherapy; Child; Childhood; Children; Cytarabine; Decitabine - therapeutic use; Down's syndrome; Epigenetics; Flow cytometry; Fludarabine; Gene expression; Hematology; Hematopoietic stem cells; Humans; Leukemia; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - genetics; Leukemia, Myeloid, Acute - pathology; Leukemogenesis; Lymphoma; Lymphoma - drug therapy; Minimal residual disease; Patients; Pediatrics; Pharmacodynamics; Stem cell transplantation; Vorinostat

Survival outcomes for relapsed/refractory pediatric acute myeloid leukemia (R/R AML) remain dismal. Epigenetic changes can result in gene expression alterations which are thought to contribute to both leukemogenesis and chemotherapy resistance. We report results from a phase I trial with a dose expa...